Radiance Biopharma
Privately held biotechnology company focused on design and clinical development of next-generation antibody–drug conjugates (ADCs) and related biologics for oncology. The company develops bispecific and monospecific ADC formats, nanobody-based ADCs, monoclonal antibodies against tumor-specific biomarkers, companion diagnostics, and pursues IND submissions and Phase I clinical development in multiple territories.
Industries
N/A
Nr. of Employees
small (1-50)
Radiance Biopharma
One Boston Place, Ste. 2600, Boston, MA 02108, USA
Products
RB-601 (c-MET / EGFR bispecific nanobody ADC)
Bispecific nanobody-based ADC targeting c-MET and EGFR using site-specific conjugation to deliver a homogeneous DAR and an MMAE payload; cleared for IND in China and subject to first-in-human studies.
RB-164 (ROR-1 targeted ADC)
Fc-silenced ADC targeting ROR-1 with site-specific conjugation and a novel linker to deliver homogeneous DAR and enhanced stability; progressed into Phase I dose-escalation trials with IND clearances reported.
RB-201 (HER2 / TROP-2 bispecific ADC)
Bispecific ADC targeting HER2 and TROP-2 for tumors co-expressing these antigens; demonstrated superior efficacy versus monospecific ADCs in preclinical models and planned first-in-human Phase Ia/b clinical trial.
RB-203 (membrane Hsp70 monoclonal antibody and companion diagnostic)
Monoclonal antibody recognizing membrane Hsp70 that selectively accumulates in tumors expressing this biomarker; paired with a patented blood ELISA test to detect exosomal Hsp70 for tumor detection and response monitoring.
RB-601 (c-MET / EGFR bispecific nanobody ADC)
Bispecific nanobody-based ADC targeting c-MET and EGFR using site-specific conjugation to deliver a homogeneous DAR and an MMAE payload; cleared for IND in China and subject to first-in-human studies.
RB-164 (ROR-1 targeted ADC)
Fc-silenced ADC targeting ROR-1 with site-specific conjugation and a novel linker to deliver homogeneous DAR and enhanced stability; progressed into Phase I dose-escalation trials with IND clearances reported.
RB-201 (HER2 / TROP-2 bispecific ADC)
Bispecific ADC targeting HER2 and TROP-2 for tumors co-expressing these antigens; demonstrated superior efficacy versus monospecific ADCs in preclinical models and planned first-in-human Phase Ia/b clinical trial.
RB-203 (membrane Hsp70 monoclonal antibody and companion diagnostic)
Monoclonal antibody recognizing membrane Hsp70 that selectively accumulates in tumors expressing this biomarker; paired with a patented blood ELISA test to detect exosomal Hsp70 for tumor detection and response monitoring.
Expertise Areas
- Antibody–drug conjugate development
- Bispecific antibody engineering
- Nanobody therapeutics
- Monoclonal antibody therapeutics
Key Technologies
- Antibody–drug conjugates (ADCs)
- Bispecific antibody formats
- Nanobody-based therapeutics
- Site-specific conjugation
News & Updates
Press release reporting an exclusive license agreement for a first-in-class c-MET/EGFR targeted nanobody ADC.
News article reporting a proposed transaction for rights to a next-generation ADC.
Press release announcing first patient dosing in a Phase I dose-escalation trial of an ROR-1 targeted ADC.
Press release reporting FDA clearance of an IND application for an ROR-1 targeted ADC to support Phase I clinical development.
Press release describing an exclusive licensing transaction for a ROR-1 targeted ADC.
Announcement of a collaboration agreement with a contract research / biologics services provider for bispecific ADC development.
Press release reporting an exclusive license agreement for a first-in-class c-MET/EGFR targeted nanobody ADC.
News article reporting a proposed transaction for rights to a next-generation ADC.
Press release announcing first patient dosing in a Phase I dose-escalation trial of an ROR-1 targeted ADC.
Press release reporting FDA clearance of an IND application for an ROR-1 targeted ADC to support Phase I clinical development.
Press release describing an exclusive licensing transaction for a ROR-1 targeted ADC.
Announcement of a collaboration agreement with a contract research / biologics services provider for bispecific ADC development.